Reported 10 days ago
Billionaire philanthropist MacKenzie Scott has reduced her stake in Amazon.com by 42% over the past year, now holding 81.1 million shares, down from 139 million. This reduction is valued at approximately $12.55 billion. Following her 2019 divorce from Jeff Bezos, Scott received a 4% stake in Amazon, but he retains voting authority over her holdings. Scott has been noted for her philanthropic efforts, donating over $19 billion to various nonprofits in recent years.
Source: YAHOO
Reported 10 days ago
HSBC has upgraded NVIDIA Corporation (NVDA) to a 'Buy' rating from 'Hold' and increased its price target to $320, citing a growing total addressable market for AI GPUs that promises steady earnings growth. The analysts project a significant rise in GPU market estimates for FY27, anticipating substantial demand recovery in China and a forecasted earnings per share increase to $8.75, surpassing prior estimates. This highlights NVIDIA’s pivotal role in the AI chip market amid rising investments in artificial intelligence.
Source: YAHOO
Reported 10 days ago
Source: BARRONS
Reported 10 days ago
Sinopec has redirected a supertanker carrying crude oil after the U.S. imposed sanctions on a significant Chinese oil terminal in Rizhao, Shandong. The tanker, originally set to unload at Rizhao, has shifted its destination to Ningbo and Zhoushan ports. The sanctions, affecting a terminal involved in receiving Iranian oil, could reduce Sinopec's crude processing by approximately 3.36% this month.
Source: YAHOO
Reported 10 days ago
JPMorgan has raised its price target for Emerson Electric Co. (NYSE:EMR) from $135 to $151 while maintaining a Neutral rating. The firm expressed a cautious view on the electrical equipment sector but acknowledged more attractive valuations. Emerson has transformed into a leaner company focused on automation and software, boasting a strong dividend growth record. While it presents promising investment potential, JPMorgan notes that some AI stocks may offer better upside opportunities.
Source: YAHOO
Reported 10 days ago
Lowe's Companies, Inc. has finalized its acquisition of Foundation Building Materials, a significant distributor of construction supplies, in a move aimed at expanding its product range and improving services for professional customers. This acquisition is expected to enhance order fulfillment speeds, digital capabilities, and access to key regions, further positioning Lowe's as a comprehensive solutions provider for homebuilders. Additionally, Lowe’s maintains a strong dividend history, having increased its payout for 60 consecutive years.
Source: YAHOO
Reported 10 days ago
On October 14, Citizens reaffirmed its 'Market Outperform' rating on Chubb Limited (NYSE:CB) and established a price target of $325, citing strong earnings growth and a robust balance sheet as key factors. Recognized for its exceptional global franchise and consistent dividend increases over 32 years, Chubb is positioned as a leading property and casualty insurer catering to high-end clientele with customized coverage options.
Source: YAHOO
Reported 10 days ago
Dover Corporation (NYSE:DOV) has seen its price target raised from $217 to $220 by JPMorgan, which maintains an Overweight rating on the stock. This adjustment comes as part of the firm's earnings preview for Q3 within the electrical equipment and multi-industry sectors. Despite a cautious outlook for the short term, JPMorgan finds current valuations appealing. Dover, known for its strong dividend history, has increased its dividend for 69 consecutive years, currently offering a quarterly dividend of $0.52 per share.
Source: YAHOO
Reported 10 days ago
BofA Securities has raised the price target for Caterpillar Inc. (NYSE:CAT) from $517 to $594, maintaining a Buy rating. The adjustment follows increased demand in the small turbine market, where supply limitations have created longer lead times and higher prices, particularly for advanced components. Additionally, BofA highlighted the growing value from data centers and Caterpillar's reliable dividend history, marking 31 years of consecutive increases.
Source: YAHOO
Reported 10 days ago
Pentair plc (NYSE:PNR), a leader in water treatment technology and a consistent dividend payer, sees increased analyst confidence as JPMorgan raises its target price from $116 to $126 while maintaining an Overweight rating. Citi also boosts its target to $133 with a Buy rating. Despite a cautious outlook on the sector, analysts find the current valuations appealing, highlighting Pentair's strong dividend history, having increased payments for 49 consecutive years.
Source: YAHOO
Reported 10 days ago
DA Davidson has maintained its Buy rating and $117 price target for Walmart Inc. (NYSE:WMT) following the retailer's partnership with OpenAI, which allows customers to shop through ChatGPT via the Instant Checkout platform. The firm notes that Walmart is well-positioned to benefit from the growing 'Agentic Commerce' trend due to its scale and proactive adoption of AI technologies. Additionally, Walmart has a strong dividend track record, having raised payouts for 52 consecutive years.
Source: YAHOO
Reported 10 days ago
Citizens JMP analyst Silvan Tuerkcan has reaffirmed a Buy rating for IDEAYA Biosciences (NASDAQ:IDYA) with a price target of $45, noting the company's promising developments, particularly in their lead asset darovasertib for uveal melanoma. J.P. Morgan also supports this outlook with a Buy rating and a $74 target, highlighting potential valuable updates in multiple treatment settings. While IDEAYA presents investment potential, analysts suggest some AI stocks may offer higher upside with lower risks.
Source: YAHOO
Reported 10 days ago
CG Oncology, Inc. (NASDAQ:CGON) has been initiated with a Buy rating by Guggenheim, who has set a price target of $90 for the stock. The firm highlights CGON's potential in the non-muscle invasive bladder cancer market, identifying its product cretostimogene as a key asset due to its efficacy and safety expected to enter FDA review in 2026. Despite its promising outlook, some analysts suggest that certain AI stocks may offer better investment opportunities.
Source: YAHOO
Reported 10 days ago
BTIG analyst Julian Harrison has maintained a Buy rating on Apogee Therapeutics Inc. (NASDAQ:APGE) with a price target of $115. The positive outlook is attributed to the company's promising clinical developments, particularly its drug APG777 which shows potential in treating asthma and other conditions. Ongoing trials and data updates are expected to confirm APG777's safety and efficacy, reinforcing the Buy recommendation.
Source: YAHOO
Reported 10 days ago
H.C. Wainwright has updated its price target for Ocular Therapeutix Inc. (NASDAQ:OCUL) from $15 to $19 while maintaining a Buy rating. This adjustment follows the FDA granting Special Protocol Assessment for AXPAXLI, intended for treating non-proliferative diabetic retinopathy. Ocular Therapeutix is involved in developing therapies for eye-related conditions and has presented trials HELIOS-2 and HELIOS-3, showcasing the potential of its product pipeline.
Source: YAHOO
Reported 10 days ago
Goldman Sachs has started coverage of Soleno Therapeutics, Inc. (NASDAQ:SLNO) with a Buy rating, setting a target price of $125. The firm anticipates that Vykat XR, Soleno's leading treatment for Prader-Willi syndrome, will become a foundational therapy and believes that the recent stock pullback offers a favorable investment opportunity.
Source: YAHOO
Reported 10 days ago
Cantor Fitzgerald analyst Olivia Brayer has reiterated a Buy rating for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), despite lowering the price target from $90 to $80. Concurrently, J.P. Morgan also supports a Buy rating, setting a higher target at $119. Recent updates from BioMarin’s studies at the ASBMR Annual Meeting indicate promising advancements in treatment efficacy for young patients. Analysts remain optimistic about BioMarin’s growth potential, especially with upcoming product expansions.
Source: YAHOO
Reported 10 days ago
H.C. Wainwright analyst Swayampakula Ramakanth recently assigned a Buy rating to Corcept Therapeutics Incorporated (CORT) with a price target of $145, despite a recent distribution shift for its drug Korlym. While recent changes might delay pharmacy operations, the analyst considers these issues temporary and advises investors to buy on dips, highlighting Corcept’s potential in treating Cushing's syndrome.
Source: YAHOO
Reported 10 days ago
J.P. Morgan analyst Jessica Fye reaffirmed a Buy rating for Legend Biotech Corporation (LEGN) on October 9, setting a price target of $76, citing the company's strong growth potential despite current supply constraints with its Carvykti product. TD Cowen also maintained a Buy rating with a target of $62, highlighting the company's strategic positioning and expectations to meet a $1.9 billion sales target for fiscal year 2025. Legend Biotech specializes in innovative therapies for oncology and operates in multiple regions, including the U.S. and China.
Source: YAHOO
Reported 10 days ago
Viking Therapeutics, Inc. (NASDAQ:VKTX) has received a Buy rating from Oppenheimer, with a price target of $100, highlighting its promising position in the healthcare sector. Analyst Joseph Pantginis also supports this view, emphasizing the company's strong efficacy and safety data in its GLP-1 programs, which position it well for potential mergers and acquisitions despite a competitive landscape.
Source: YAHOO
Reported 10 days ago
Freedom Capital Markets has assigned a 'Buy' rating to Toast, Inc. (NYSE:TOST) and set a price target of $45. The firm recognizes Toast's successful entry into the US restaurant sector, achieving a presence in about 15% of restaurant locations since 2011. With anticipated growth in market share among small and medium businesses and opportunities in enterprise and international markets, Toast is expected to drive sustained growth in key performance metrics.
Source: YAHOO
Reported 10 days ago
Raymond James has reduced its price target for Shift4 Payments, Inc. (NYSE:FOUR) from $126 to $120 while maintaining a Strong Buy rating ahead of the company's Q3 2025 results. This adjustment reflects anticipated weaknesses in its recent acquisition, Global Blue, prompting downward revisions in revenue and EBITDA estimates for Q3 and fiscal years 2026-2027. Despite these concerns, Raymond James remains optimistic about Shift4's core business performance and long-term growth potential through revenue synergies.
Source: YAHOO
Reported 10 days ago
TD Cowen has reaffirmed its Buy rating for Fiserv, Inc. (NYSE:FI) with a price target of $188, following the company's Forum 2025 event that emphasized its innovative strategies and integration efforts between its Financial Services and Merchant Solutions divisions. Analysts at TD Cowen are optimistic about Fiserv's growth potential, notably highlighting its Clover payment system and improvements across its product offerings.
Source: YAHOO
Reported 10 days ago
William Blair 于10月10日将 nCino, Inc. (NASDAQ:NCNO) 从市场表现升级为跑赢大盘，认为近期银行技术股的抛售过于剧烈，为投资者提供了良好的入场时机。nCino 预计到2027财年末达到40%的健康标准，并计划通过国际扩展和信贷合作增强长期增长。同时，William Blair 认为 nCino 的更保守的预测方法增加了未来超出市场预期的可能性。
Source: YAHOO